Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK

ConclusionThere was no evidence for a difference in dementia risk between AI and tamoxifen users among postmenopausal breast cancer survivors.Implications for Cancer SurvivorsOur findings suggest that there is no reason for concern about a difference in dementia risk with AI vs. tamoxifen, which is relevant to postmenopausal breast cancer patients recommended these treatments.
Source: Journal of Cancer Survivorship - Category: Cancer & Oncology Source Type: research